Canntab to Launch in Australia and Participate in Australia’s Largest Cannabis Research Study

TORONTO, Oct. 26, 2020 /PRNewswire/ – Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the impending launch of its suite of hard pill cannabinoid formulations in Australia with its partner CANN Global Ltd. (ASX: CGB) (“CANN Global”)

CANN Global through its management partnership with Medcan Australia Pty Ltd (“Medcan Australia”), received an import permit and have placed an initial order for Canntab’s products. Canntab will immediately apply for an export permit with Health Canada, which will allow it to fulfill this purchase order. The Company intends to ship its suite of Patented and Patent Pending products, including THC, CBD and THC/CBD combination hard pill formulations to CANN Global before the end of 2020. Once the products are shipped to CANN Global in Australia, the products will be…